Skip to main content

Table 1 Demographic and clinical characteristics of the patients

From: Combination of computed tomography imaging-based radiomics and clinicopathological characteristics for predicting the clinical benefits of immune checkpoint inhibitors in lung cancer

Characteristic Training cohort Validation cohort p-value
(n = 64) (n = 28)  
Sex, n. (%)    0.086
 Female 14 (21.88) 11 (39.29)  
 Male 50 (78.12) 17(60.71)  
Age(years), mean (SD) 20.44 (8.98) 20.04 (8.99) 0.844
Smoking status, n. (%)    0.656
 No 34 (53.10) 17 (60.7)  
 Yes 30 (46.90) 11 (39.3)  
Family history, n. (%)    0.754
 No 62 (96.90) 26 (92.9)  
 Yes 2 (3.10) 2 (7.1)  
TTF-1, n. (%)    0.070
 Negative 42 (65.60) 12 (42.9)  
 Positive 22 (34.40) 16 (57.1)  
Ki-67, n. (%)    0.560
 Low expression 33 (51.60) 17 (60.7)  
 High expression 31 (48.40) 11 (39.3)  
Histologic type, n. (%)    0.120
 Adenocarcinoma 32 (50.00) 20 (71.43)  
 Squamous cell carcinoma 28 (43.80) 6 (21.43)  
 NOS 4 (6.20) 2 (7.14)  
Stage, n. (%)    0.257
 Ш 23 (35.90) 6 (21.40)  
 IV 41 (64.10) 22 (78.60)  
T stage, n. (%)    0.842
 0 1 ( 1.60) 0 ( 0.00)  
 1 8 (12.50) 3 (10.70)  
 2 20 (31.20) 11 (39.30)  
 3 9 (14.10) 5 (17.90)  
 4 26 (40.60) 9 (32.10)  
N stage, n. (%)    0.821
 0 6 (9.38) 3 (10.70)  
 1 5 (7.81) 1 (3.60)  
 2 25 (39.06) 13 (46.40)  
 3 28 (43.75) 11 (39.30)  
M stage, n. (%)    0.176
 0 22 (34.40) 5 (17.90)  
 1 42 (65.60) 23 (82.10)  
Lymph node metastasis, n. (%)    0.880
 No 9 (14.10) 5 (17.90)  
 Yes 55 (85.90) 23 (82.10)  
Intrapulmonary metastasis, n. (%)    0.466
 No 39 (60.90) 20 (71.40)  
 Yes 25 (39.10) 8 (28.60)  
Brain metastasis, n. (%)    0.330
 No 55 (85.90) 21 (75.00)  
 Yes 9 (14.10) 7 (25.00)  
Liver metastasis, n. (%)    1.000
 No 59 (92.20) 026 (92.90)  
 Yes 5 ( 7.80) 2 (7.10)  
Bone metastasis n. (%)    1.000
 No 44 (68.80) 019 (67.90)  
 Yes 20 (31.20) 9 (32.10)  
Pleural metastasis n. (%)    0.073
 No 54 (84.38) 19 (67.86)  
 Yes 10 (15.62) 9 (32.14)  
White blood cell, (median [IQR]) 6.40 [4.47, 7.78] 6.15 [5.00, 8.33] 0.333
Neutrophil, (median [IQR]) 69.05 [62.65,73.78] 65.20 [58.50, 71.08] 0.203
Monocyte, (median [IQR]) 8.65 [6.83, 11.03] 6.70 [5.27, 9.45] 0.952
CRP, (median [IQR]) 18.10 [5.05, 19.85] 12.00 [1.17, 18.83] 0.330
CEA, (median [IQR]) 13.60 [3.88, 84.30] 11.30 [2.80, 84.30] 0.568
NSE, (median [IQR]) 14.25 [10.35, 19.10] 15.05 [12.00, 19.10] 0.513
PD-L1 expression, n. (%)    0.9276
 < 1% 30 (46.88) 12 (42.86)  
 ≥ 1% 12 (18.75) 6 (21.43)  
 Unknown 22 (34.37) 10 (35.71)  
Therapy line, n. (%)    0.7251
 1st 23 (35.94) 9 (32.14)  
 ≥ 2nd 41 (64.06) 19 (67.86)  
Immunotherapy regimen, n. (%)    0.9366
 PD-1 inhibitors 36 (56.25) 16 (57.14)  
 PD-1 inhibitors + chemotherapy 28 (43.75) 12 (42.86)  
  1. CRP C-reactive protein, CEA carcinoembryonic antigen, NSE neuron-specific enolase, NOS not otherwise specified, four are adenosquamous carcinoma and two are small cell lung cancer